Video

Q&A With Emmanuel Labourier From BMDx Consulting: Molecular Diagnostics Provides Clearer Picture for Thyroid Cancer Testing

Author(s):

Patients being tested for thyroid cancer want to know they are receiving the most accurate information possible following the test. A new method could help provide both answers for patients and direction for doctors about the best course of action.

Patients being tested for thyroid cancer want to know they are receiving the most accurate information possible following the test. A new method could help provide both answers for patients and direction for doctors about the best course of action.

Emmanuel Labourier, PhD, discussed one such test which was recently released on the market during the AACE's 24th Annual Scientific and Clinical Congress in Nashville. Labourier said that in the United States alone close to one half of a million "suspicious," nodules will be tested this year making the need for clear results that much more important. That can also determine whether a patient needs or can avoid underoing a surgical procedure.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.